SCHEDULE 13G 0001856083 XXXXXXXX LIVE Ordinary shares, nominal value 0.01 EUR per share 01/23/2026 0001756594 Inventiva S.A. 46124U107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 11668983.00 0.00 11668983.00 11668983.00 N 6.07 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 11668983.00 0.00 11668983.00 11668983.00 N 6.07 CO David Kroin b X1 0.00 11668983.00 0.00 11668983.00 11668983.00 N 6.07 HC IN Inventiva S.A. 50 Rue De Dijon, Daix, France, 21121 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 11,668,983 6.07% 0 11,668,983 0 11,668,983 Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of January 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 192,329,222 shares outstanding as of December 31, 2025, as disclosed by Inventiva S.A. on its website in accordance with article 223-16 of the general regulations of the AMF (French Financial Markets Authority). The beneficially owned shares include 8,504,604 Ordinary Shares, 3,164,379 American Depository Shares ("ADS"), and 9,999,999 Warrants exercisable at an exercise price of 1.50 EUR, subject to the occurrence of a T3 Triggering Event, and subject to the Reporting Persons' beneficial ownership of 4.99% (the "Maximum Percentage") of the outstanding Ordinary Shares. The T3 Triggering event is subject to the release by the Company of topline data announcing that any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH), with any dosage regimen tested in the trial, have been met no later than June 15, 2027. The exercise of the Warrants must take place no later than July 30, 2027. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 46124U107 has been assigned to the ADS of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents 1 Ordinary Share. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: January 30, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP /s/ David Kroin 01/30/2026 Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin 01/30/2026 David Kroin /s/ David Kroin 01/30/2026